<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03477630</url>
  </required_header>
  <id_info>
    <org_study_id>PRP 3.5 - 01 versión 1.0</org_study_id>
    <nct_id>NCT03477630</nct_id>
  </id_info>
  <brief_title>Treatment of Osteoarthrosis of the Knee With Platelet Rich Plasma, Comparative Study With Hyaluronic Acid</brief_title>
  <official_title>Active Controlled, Randomized, Open Trial of Rich Plasma Platelets and Hyaluronic Acid for Osteoarthrosis of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karla Andrea Arias Varela</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Varela, Karla Andrea Arias, M.D.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is using Plasma Rich Platelets to improve the negative symptoms of adult patients
      with osteoarthrosis of the knee. Half of the patients receive Plasma Rich Platelets. The
      other half receives hyaluronic acid.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Platelet Rich Plasma and hyaluronic acid are treatments injected directly into diseased
      knees. Both products reduce negative symptoms such as pain and inflammation. But they use
      different mechanisms. Plasma is a biological product that acts mainly as an anti-inflammatory
      reducing pain and collaborating to re establish the chemical balance within the knee, which
      slows down the deterioration of the joint.

      Hyaluronic acid is a knee lubricant that decreases friction and therefore stress inside the
      knee.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 4, 2018</start_date>
  <completion_date type="Anticipated">December 4, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 4, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>asignación paralela</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in pain intensity measures and functional limitation of the knee</measure>
    <time_frame>Day 0, 3 months, 6 months, 12 months.</time_frame>
    <description>2 item of Scale EVA for pain intensity associated with the activities of daily life as well as sports activities if practiced. Each item scored 0-100 ( 0: no pain, 100: pain as bad as can be). 11 item for Scale Lequesne.The total score is within the range between 0-24 points. Based on it, a severity scale is established: extremely serious, very serious, severe, moderate and mild. Scale Womac consists of 24 items. Each one is divided into 5 possible answers: none, little, enough, a lot and the highest.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Platelet Rich Plasma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infiltration injected 8 cc per session, 4 sessions, 1 session every 15 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hyaluronic Acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Infiltration, injected 6 cc per session, 1 sessions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Platelet Rich Plasma</intervention_name>
    <description>Infiltration PRP 8cc per session, 4 sessions, 1 session every 15 days.</description>
    <arm_group_label>Platelet Rich Plasma</arm_group_label>
    <other_name>PRP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyaluronic Acid</intervention_name>
    <description>Infiltration 6 cc of HA , only once.</description>
    <arm_group_label>Hyaluronic Acid</arm_group_label>
    <other_name>HA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Osteoarthrosis grade II, III and IV of Kellgren and Lawrence

          2. Chronic painful knee of mechanical characteristics.

          3. Absence of local or systemic septic process.

          4. Hematological and biochemical alterations that contraindicate the treatment.

          5. Informed consent in writing from the patient.

          6. The patient is able to understand the nature of the study

        Exclusion Criteria:

          1. Allergic to the egg

          2. Alteration in blood tests for platelet count in whole blood (hemogram)

          3. Patients presenting positive serology for HIV 1 and 2, Hepatitis B [HBsAg,
             Anti-HBV-Ab], Hepatitis C [Anti-HCV-Ab] and Lúes ).

          4. Congenital or evolutive diseases that translate malformation and / or significant
             deformations of the knee, which hinder the application or evaluation of the results.

          5. Weight overload expressed in body mass index (BMI) greater than 30.5 (obesity grade
             II). Being BMI = mass (Kg): (height (m)) 2.

          6. Simultaneous participation in another clinical trial or treatment with another product
             in the experimental phase in the 30 days prior to inclusion in the study.

          7. Neoplastic disease

          8. Immunosuppressive states.

          9. Other pathologies or circumstances that compromise participation in the study
             according to medical criteria.

         10. The participant who has received intra-articular injection in knee with steroid
             deposit in the last 3 months. .

         11. Participant with religious or cultural conflicts due to the use of Platelet Rich
             Plasma.

         12. Participant who presents before the procedure a platelet count in whole blood outside
             the range of normality (150.00 to 450,000).

         13. Participant with infectious diseases active in blood.

         14. Patients with anticoagulant treatment (warfarin, heparin) in the last 6 months.

         15. Participant with a history of skin, muscle or bone cancer in the lower limbs.

         16. Participant with psychological, emotional, social problems or any other situation that
             may interfere with the requirements of the study.

         17. Participant hospitalized for medical or surgical reasons.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karla Arias Varela</last_name>
    <role>Study Director</role>
  </overall_official>
  <overall_contact>
    <last_name>Karla Arias Varela</last_name>
    <phone>89146496</phone>
    <email>karias@ccocr.com</email>
  </overall_contact>
  <reference>
    <citation>Riboh JC, Saltzman BM, Yanke AB, Fortier L, Cole BJ. Effect of Leukocyte Concentration on the Efficacy of Platelet-Rich Plasma in the Treatment of Knee Osteoarthritis. Am J Sports Med. 2016 Mar;44(3):792-800. doi: 10.1177/0363546515580787. Epub 2015 Apr 29.</citation>
    <PMID>25925602</PMID>
  </reference>
  <reference>
    <citation>Carrillo-Mora P, González-Villalva A, Macías-Hernández SI, Villaseñor CP. [Platelets-rich plasma: a versatile tool for regenerative medicine?]. Cir Cir. 2013 Jan-Feb;81(1):74-82. Review. Spanish.</citation>
    <PMID>23461926</PMID>
  </reference>
  <reference>
    <citation>Shahid M, Kundra R. Platelet-rich plasma (PRP) for knee disorders. EFORT Open Rev. 2017 Mar 13;2(1):28-34. doi: 10.1302/2058-5241.2.160004. eCollection 2017 Jan. Review.</citation>
    <PMID>28607768</PMID>
  </reference>
  <results_reference>
    <citation>Raeissadat SA, Rayegani SM, Hassanabadi H, Fathi M, Ghorbani E, Babaee M, Azma K. Knee Osteoarthritis Injection Choices: Platelet- Rich Plasma (PRP) Versus Hyaluronic Acid (A one-year randomized clinical trial). Clin Med Insights Arthritis Musculoskelet Disord. 2015 Jan 7;8:1-8. doi: 10.4137/CMAMD.S17894. eCollection 2015.</citation>
    <PMID>25624776</PMID>
  </results_reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2018</study_first_submitted>
  <study_first_submitted_qc>March 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2018</study_first_posted>
  <last_update_submitted>March 19, 2018</last_update_submitted>
  <last_update_submitted_qc>March 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Varela, Karla Andrea Arias, M.D.</investigator_affiliation>
    <investigator_full_name>Karla Andrea Arias Varela</investigator_full_name>
    <investigator_title>Clinical Research</investigator_title>
  </responsible_party>
  <keyword>gonarthrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

